Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Noonan syndrome caused by mutations in the PTPN11 gene.
Features include very common findings: Cryptorchidism; and common findings: Epicanthus, Short stature, Hypertelorism, and Pulmonic stenosis and others. 57 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Head and neck | 4 | Cleft palate, High, narrow palate, Triangular face |
PTPN11 function has not been fully characterized.
Noonan syndrome 1 is associated with mutations in the PTPN11 gene on chromosome 12.
No clinically relevant genotype-phenotype correlations for BRAF, KRAS, LZTR1, MAP2K1, MRAS, NRAS, RAF1, RASA2, RIT1, RRAS2, SOS1, or SOS2 have been identified.
No consensus clinical diagnostic criteria for Noonan syndrome have been published. Diagnostic scoring systems, most recently published in and embedded in the management guidelines developed by DYSCERNE in the United Kingdom , have been proposed but have not been used extensively in North America.
Noonan syndrome (NS) should be suspected in individuals with the following clinical, laboratory, and family history findings.
Clinical findings
Source:
No approved treatments are currently available for Noonan syndrome 1. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for Noonan syndrome 1, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for Noonan syndrome 1. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
Table 8. Noonan Syndrome: Recommended Surveillance
System/Concern |
|---|
No clinical trials have been registered for Noonan syndrome 1.
148 publications have been identified in PubMed for Noonan syndrome 1. Research spans Basic Science / Preclinical (30%), Review / Meta-Analysis (26%), and Case Report / Case Series (16%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 45 | 30% |
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 3:05 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about Noonan syndrome 1
3 |
Failure to thrive in infancy, Short stature, Postnatal growth retardation |
Heart and blood vessels | 3 | Ventricular septal defect, Thickened heart muscle (hypertrophic cardiomyopathy), Atrial septal defect |
Blood and immune system | 2 | Abnormal bleeding tendency (abnormal bleeding), Amegakaryocytic thrombocytopenia |
Ears | 2 | Hearing loss (hearing impairment), Inner ear hearing loss (sensorineural hearing impairment) |
Skin | 2 | Dry skin, Lymphedema |
Hormones | 2 | Male infertility, Hypogonadism |
Arms and legs | 1 | Radial deviation of finger |
Brain and nerves | 1 | Intellectual disability |
Bones and joints | 1 | Kyphoscoliosis |
Digestive system | 1 | Feeding difficulties in infancy |
Eyes | 1 | Ptosis |
Age of onset: at birth, infancy.
To date, including those with a clinical and a molecular genetic diagnosis and with an estimated incidence of 1:1000-1:2500, several thousand individuals have been identified with Noonan syndrome (NS) . The following description of the phenotypic features associated with this condition is based on these reports. Table 2. Noonan Syndrome: Frequency of Select Features
Feature | % of Personsw/Feature | Comment |
|---|---|---|
Eye anomalies | 95% | — |
Short stature | 50%-70% | For age, sex, family background |
Hypotonia | Majority | Can contribute to feeding problems, speech articulation issues, delayed attainment of gross motor milestones |
Joint hyperextensibility | Majority | — |
Pectus anomaly | Majority | Characteristic pectus deformity of the chest: pectus carinatum superiorly pectus excavatum inferiorly |
Cryptorchidism in males | 60%-80% | — |
Congenital heart disease | 50%-80% | 25%-71% of affected persons have pulmonary valve stenosis, often w/pulmonary valve dysplasia. |
Hearing loss | 40% | May be sensorineural, conductive, or mixed |
Hypertrophic cardiomyopathy | 10%-29% | Half of those w/hypertrophic cardiomyopathy are diagnosed by age 6 mos. |
Learning disability | 25% | ~10%-15% of those w/NS require special education. |
Intellectual disability1 | 6%-23% Renal anomalies | 11% |
Abnormal bleeding or bruising | Bleeding: 6%-10%; bruising: majority | 1. Defined as IQ 70 Prenatal features. Advanced paternal age has been observed in cohorts with simplex NS. |
Source: GeneReviews — "Noonan Syndrome"
PTPN11
Germline pathogenic variants at codons 61, 71, 72, and 76 are significantly associated with leukemogenesis and identify a subgroup of individuals with NS at risk for JMML .
Individuals with the pathogenic variant are said to be more likely to receive a typical education .
An in-frame three-nucleotide PTPN11 deletion in a female infant with severe features of Noonan syndrome, including hydrops fetalis and juvenile myelomonocytic leukemia , has been reported. The three-nucleotide PTPN11 deletion has also been reported in a child with typical rather than severe NS .
Source: GeneReviews — "Noonan Syndrome"
Turner syndrome, typically seen in females, is differentiated from Noonan syndrome (NS) by demonstration of a sex chromosome abnormality on cytogenetic studies in affected individuals. The phenotype of Turner syndrome is quite different from that of NS, when one considers face, heart, development, and kidneys. In Turner syndrome, renal anomalies are more common, developmental delay is much less frequently found, and left-sided heart defects are the rule. Genes of interest in the differential diagnosis of NS are summarized in .
Table 5.
Noonan Syndrome: Differential Diagnosis
Gene(s) | Disorder | MOI | Clinical Characteristics / Comment
BRAFKRASMAP2K1MAP2K21 | Cardiofaciocutaneous syndrome | AD | See .
BRAF
MAP2K1
PTPN11
Source: GeneReviews — "Noonan Syndrome"
Genetic testing for PTPN11 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for Noonan syndrome 1 has been reported in the published literature.
Designated
Exclusivity End |
|---|
Designation Status |
|---|
Norditropin | Somatropin | Novo Nordisk Inc. | 2006 | 2014 | Designated (drug approved for other indication) |
Management guidelines have been developed by DYSCERNE, a European consortium (full text); a separate set has been published by the American Academy of Pediatrics working with the Noonan Syndrome Support Group and in the Lancet . Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with Noonan syndrome, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 6. Noonan Syndrome: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment |
|---|---|---|
Constitutional | Measurements of growth parameters | On NS-specific growth charts; To identify those w/failure to thrive /or short stature |
Endocrine | Bone age, growth hormone thyroid function studies1 | In children w/short stature (height 2 SD below standard growth curve or crossing 2 major height %iles) Gastrointestinal/ |
Feeding | Gastroenterology / nutrition / feeding team eval | In infants w/poor weight gain, dysphagia; Eval for malrotation if persistent unexplained vomiting |
Development | Developmental assessment | To incl:; Motor, adaptive, cognitive, speech-language eval; Eval for early intervention/ special education Psychiatric/ |
Behavioral | Neuropsychiatric eval may be considered. | For those age 12 mos: screen for behavior concerns, autism, depression, ADHD, anxiety (some symptoms may not be present until adulthood). |
Cardiovascular | Echocardiogram EKG | To identify congenital heart defects, cardiomyopathy, /or cardiac conduction abnormalities |
Genitourinary | Kidney ultrasound | To assess for renal anomalies; if present, referral to urologist Assessment for cryptorchidism in males |
Musculoskeletal | PT/OT eval | To incl:; Assessment of gross motor fine motor skills Consider radiographs of the spine if asymmetry or scoliosis is present on physical exam. |
Lymphatic | In consultation w/hematologist: bleeding history, CBC w/differential, PT/aPTT, factor XI, XII, IX, VIII, vWf, platelet aggregation testing | If initial screening was performed before age 12 mos, repeat after age 12 mos.2 |
Eyes | Ophthalmologic eval | To assess for amblyopia, refractive error, nystagmus, strabismus, clinically significant ptosis |
Hearing | Audiologic eval | Assess for hearing loss middle ear effusion. |
Integument | Full skin exam | Consider referral to dermatologist in those w/multiple lentigines requiring monitoring or significant xeroderma.3 |
Neurologic | Neurologic eval | To incl brain spine MRI if signs or symptoms consistent w/possible Chiari malformation Genetic |
counseling | By genetics professionals4 | To obtain a pedigree inform affected persons their families re nature, MOI, implications of NS to facilitate medical personal decision making Family support resources |
Noonan Syndrome: Treatment of Manifestations Manifestation/Concern | Treatment | Considerations/Other |
Short stature | GH therapy may be considered. | No standard dose has been established.; No apparent correlation between dosage used final height, though earlier age at initiation of GH therapy is assoc w/ final adult height.; Short stature due to NS is an FDA-approved indication for GH treatment. |
difficulties | Consideration of nasogastric tube feedings in infants w/poor growth, esp if they have a congenital heart defect or cardiomyopathy | Invasive intervention (i.e., placement of gastrostomy tube) may be needed, though feeding issues are often self-limited. DD/ID |
Source: GeneReviews — "Noonan Syndrome"
Aspirin therapy should be avoided because it may exacerbate a bleeding diathesis.
Source: GeneReviews — "Noonan Syndrome"
The MEK inhibitor trametinib was given under compassionate use to two infants with pathogenic variants in RIT1 and progressive, congenital hypertrophic cardiomyopathy. Trametinib is a highly selective reversible allosteric inhibitor of MEK1/2 activity. In both cases, there was reversal of progressive myocardial hypertrophy and valvar obstruction along with a catch-up pattern of somatic growth . reported an individual age 14 years with SOS1-related NS who had resolution of mesenteric and retroperitoneal lymphangiectasia and chylothorax after treatment with trametinib, with complete remodeling of the lymphatic system.
Source: GeneReviews — "Noonan Syndrome"
View trials for Noonan syndrome 1
Frequency |
|---|
Behavioral | Behavioral assessment for anxiety, attention, depression | At each visit starting in early childhood, as age appropriate |
Cardiovascular | In children 5 yrs: if initial cardiac eval is normal | At least annual cardiac eval until age 5 yrs or as clinically indicated In children 5 yrs through adulthood |
Eyes | Ophthalmology eval | Annually in childhood adolescence or as clinically indicated |
Hearing | Audiology eval | Annually in early childhood or as clinically indicated Malignancy/ |
JMML2 | For those w/pathogenic PTPN11 or KRAS variants3: consider physical exam w/assessment of spleen size CBC. | Every 3-6 mos until age 5 yrs Coagulation/ |
Bleeding | In consultation w/hematologist: bleeding history, CBC w/differential, PT/aPTT, factor XI, XII, IX, VIII, vWf, platelet aggregation testing | Prior to any surgical procedure or if there is a bleeding history CBC = complete blood count; PT/aPTT = prothrombin/activated partial thromboplastin time; vWF = von Willebrand factor; JMML = juvenile myelomonocytic leukemia; OSA = obstructive sleep apnea 1. |
Source: GeneReviews — "Noonan Syndrome"
Phenotype severity distribution: 1 very common feature, 15 common features.
39 |
26% |
Patient case studies | 23 | 16% |
Disease patterns and progression | 22 | 15% |
Clinical study results | 9 | 6% |
Testing and diagnosis research | 5 | 3% |
New treatment approaches | 3 | 2% |
Other research | 2 | 1% |
Plank JR (2026). [PMID: 41905474](https://pubmed.ncbi.nlm.nih.gov/41905474/). *Biol Psychiatry Cogn Neurosci Neuroimaging*. [Basic Science / Preclinical]
Weaver KN (2026). [PMID: 41230721](https://pubmed.ncbi.nlm.nih.gov/41230721/). *Curr Opin Pediatr*. [Review / Meta-Analysis]
Jirova B (2026). [PMID: 41577878](https://pubmed.ncbi.nlm.nih.gov/41577878/). *Eur J Pediatr*. [Epidemiology / Natural History]
Yılmaz M (2026). [PMID: 40746088](https://pubmed.ncbi.nlm.nih.gov/40746088/). *Turk Kardiyol Dern Ars*. [Case Report / Case Series]
Pescini A (2026). [PMID: 41015786](https://pubmed.ncbi.nlm.nih.gov/41015786/). *J Pediatr Endocrinol Metab*. [Review / Meta-Analysis]
Jorge AAL (2026). [PMID: 41774755](https://pubmed.ncbi.nlm.nih.gov/41774755/). *Eur J Endocrinol*. [Clinical Trial Publication]
Kohanbash G (2026). [PMID: 41646294](https://pubmed.ncbi.nlm.nih.gov/41646294/). *Res Sq*. [Basic Science / Preclinical]
Monika F (2026). [PMID: 42193013](https://pubmed.ncbi.nlm.nih.gov/42193013/). *Cancers (Basel)*. [Review / Meta-Analysis]
Mammadova N (2026). [PMID: 40518752](https://pubmed.ncbi.nlm.nih.gov/40518752/). *Clin Genet*. [Case Report / Case Series]
Hirabayashi S (2026). [PMID: 41354631](https://pubmed.ncbi.nlm.nih.gov/41354631/). *Am J Hematol*. [Other]